The estimated Net Worth of Andrew D Dickinson is at least $18.2 Milion dollars as of 10 September 2024. Mr. Dickinson owns over 3,641 units of Gilead Sciences stock worth over $11,380,245 and over the last 5 years he sold GILD stock worth over $1,228,900. In addition, he makes $5,609,470 as Chief Financial Officer i Executive Vice President at Gilead Sciences.
Andrew has made over 28 trades of the Gilead Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,641 units of GILD stock worth $294,703 on 10 September 2024.
The largest trade he's ever made was exercising 10,419 units of Gilead Sciences stock on 10 March 2023 worth over $843,314. On average, Andrew trades about 2,674 units every 49 days since 2019. As of 10 September 2024 he still owns at least 140,601 units of Gilead Sciences stock.
You can see the complete history of Mr. Dickinson stock trades at the bottom of the page.
Andrew D. Dickinson serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Dickinson serves as Gilead’s Executive Vice President and Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations. Mr. Dickinson joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Mr. Dickinson drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Mr. Dickinson was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006. Mr. Dickinson received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago..
As the Chief Financial Officer i Executive Vice President of Gilead Sciences, the total compensation of Andrew Dickinson at Gilead Sciences is $5,609,470. There are 3 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.
Andrew Dickinson is 50, he's been the Chief Financial Officer i Executive Vice President of Gilead Sciences since 2019. There are 21 older and 2 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
Andrew's mailing address filed with the SEC is GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404.
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger oraz John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: